Format

Send to

Choose Destination
J Immunol Res. 2014;2014:569819. doi: 10.1155/2014/569819. Epub 2014 Jun 12.

Monocytes as regulators of inflammation and HIV-related comorbidities during cART.

Author information

1
Department of Microbiology, The University of the West Indies, Kingston, Jamaica.
2
Centre for Biomedical Research, Macfarlane Burnet Institute for Medical Research and Public Health, GPO Box 2284, Melbourne, VIC 3001, Australia ; School of Applied Sciences, RMIT University, Melbourne, VIC 3000, Australia.
3
Centre for Biomedical Research, Macfarlane Burnet Institute for Medical Research and Public Health, GPO Box 2284, Melbourne, VIC 3001, Australia ; Department of Medicine, Monash University, Melbourne, VIC 3800, Australia ; Department of Infectious Diseases, Monash University, Melbourne, VIC 3800, Australia.
4
Centre for Biomedical Research, Macfarlane Burnet Institute for Medical Research and Public Health, GPO Box 2284, Melbourne, VIC 3001, Australia.

Abstract

Combined antiretroviral therapy (cART) extends the lifespan and the quality of life for HIV-infected persons but does not completely eliminate chronic immune activation and inflammation. The low level of chronic immune activation persisting during cART-treated HIV infection is associated with the development of diseases which usually occur in the elderly. Although T-cell activation has been extensively examined in the context of cART-treated HIV infection, monocyte activation is only beginning to be recognized as an important source of inflammation in this context. Here we examine markers and sources of monocyte activation during cART-treated HIV infection and discuss the role of monocytes during cardiovascular disease, HIV-associated neurocognitive disorder, and innate immune aging.

PMID:
25025081
PMCID:
PMC4082935
DOI:
10.1155/2014/569819
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center